Association of Apolipoprotein E Polymorphism with Intravitreal Ranibizumab Treatment Outcomes in Age-Related Macular Degeneration

Current Eye Research

Volumn 41, Issue 6, 2016, Pages 862-866

  Bakbak, Berker ^a   Ozturk, Banu Turgut ^a   Zamani, Ayşe Gul ^b   Gonul, Saban ^a   Iyit, Neslihan ^a   Gedik, Sansal ^a   Yıldırım, M Selman ^b  

^a SELCUK UNIVERSITY   (Turkey)

^b NECMETTIN ERBAKAN UNIVERSITY   (Turkey)

Author keywords

Age related macular degeneration; ApoE; Apolipoprotein E; ranibizumab

Indexed keywords

APOLIPOPROTEIN E; GENOMIC DNA; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; DNA; VASCULOTROPIN A;

ADULT; AGE RELATED MACULAR DEGENERATION; ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SMOKING; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL ACUITY; AGED; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; FOLLOW UP; GENETIC POLYMORPHISM; GENETICS; INTRAVITREAL DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY; WET MACULAR DEGENERATION;

AGED; ANGIOGENESIS INHIBITORS; APOLIPOPROTEINS E; DNA; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; RANIBIZUMAB; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WET MACULAR DEGENERATION;

EID: 84945242214     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713683.2015.1067325     Document Type: Article

References (30)

1. A.Orlin, D.Hadley, W.Chang, A.C.Ho, G.Brown, R.S.Kaiser,. Association between high-risk disease loci and response to anti-vascular endothelial growth factor treatment for wet age-related macular degeneration. Retina 2012;32:4–9
2. M.Votruba, Z.Gregor. Neovascular age-related macular degeneration: present and future treatment options. Eye (London) 2001;15:424–429
3. J.Tuo, C.M.Bojanowski, C.C.Chan. Genetic factors of age-related macular degeneration. Prog Retin Eye Res 2004;23:229–249
4. L.S.Lim, P.Mitchell, J.M.Seddon, F.G.Holz, T.Y.Wong. Age-related macular degeneration. Lancet 2012;379:1728–1738
5. P.K.Kaiser. Emerging therapies for neovascular age-related macular degeneration: drugs in the pipeline. Ophthalmology 2013;120:S11–S15
6. D.Veritti, V.Sarao, P.Lanzetta. Neovascular age-related macular degeneration. Ophthalmologica 2012;227:11–20
7. P.J.Rosenfeld, D.M.Brown, J.S.Heier, D.S.Boyer, P.K.Kaiser, C.Y.Chung,. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419–1431
8. D.M.Brown, M.Michels, P.K.Kaiser, J.S.Heier, J.P.Sy, T.Ianchulev; ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009;116:57e5–65e5
9. G.A.Lalwani, P.J.Rosenfeld, A.E.Fung, S.R.Dubovy, S.Michels, W.Feuer,. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009;148:43e1–58e1
10. B.Kloeckener-Gruissem, D.Barthelmes, S.Labs, C.Schindler, M.Kurz-Levin, S.Michels,. Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD. Invest Ophthalmol Vis Sci 2011;52:4694–4702
11. M.B.Gorin, J.C.Breitner, P.T.De Jong, G.S.Hageman, C.C.ver, M.H.Kuehn,. The genetics of age-related macular degeneration. Mol Vis 1999;5:29
12. A.Thakkinstian, S.Bowe, M.McEvoy, W.Smith, J.Attia. Association between apolipoprotein E polymorphisms and age-related macular degeneration: a HuGE review and meta-analysis. Am J Epidemiol 2006;164:813–822
13. C.C.Klaver, M.Kliffen, C.M.van Duijn, A.Hofman, M.Cruts, D.E.Grobbee,. Genetic association of apolipoprotein E with age-related macular degeneration. Am J Hum Genet 1998;63:200–206
14. N.Gotoh, S.Kuroiwa, T.Kikuchi, J.Arai, S.Arai, N.Yoshida,. Apolipoprotein E polymorphisms in Japanese patients with polypoidal choroidal vasculopathy and exudative age-related macular degeneration. Am J Ophthalmol 2004;138:567–573
15. W.1.Huang, C.Qiu, E.von Strauss, B.Winblad, L.Fratiglioni. APOE genotype, family history of dementia, and Alzheimer disease risk: a 6-year follow-up study. Arch Neurol 2004;61:1930–1934
16. E.H.Souied, P.Benlian, P.Amouyel, J.Feingold, J.P.Lagarde,. The epsilon4 allele of the apolipoprotein E gene as a potential protective factor for exudative age-related macular degeneration. Am J Ophthalmol 1998;125:353–359
17. P.N.Baird, E.Guida, D.T.Chu, H.T.Vu, R.H.Guymer. The epsilon2 and epsilon4 alleles of the apolipoprotein gene are associated with age-related macular degeneration. Invest Ophthalmol Vis Sci 2004;45:1311–1315
18. P.N.Baird, A.J.Richardson, L.D.Robman, P.N.Dimitrov, G.Tikellis, C.A.McCarty,. Apolipoprotein (APOE) gene is associated with progression of age-related macular degeneration (AMD). Hum Mutat 2006;27:337–342
19. M.McKibbin, M.Ali, S.Bansal, P.D.Baxter, K.West, G.Williams,. CFH, VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration. Br J Ophthalmol 2012;96:208–212
20. D.Smailhodzic, P.S.Muether, J.Chen, A.Kwestro, A.Y.Zhang, A.Omar,. Cumulative effect of risk alleles in CFH, ARMS2, and VEGFA on the response to ranibizumab treatment in age-related macular degeneration. Ophthalmology 2012;119:2304–2311
21. K.Yamashiro, K.Tomita, A.Tsujikawa, I.Nakata, Y.Akagi-Kurashige, M.Miyake,. Factors associated with the response of age-related macular degeneration to intravitreal ranibizumab treatment. Am J Ophthalmol 2012;154:125–136
22. S.S.1.Wickremasinghe, J.Xie, J.Lim, D.S.Chauhan, L.Robman, A.J.Richardson,. Variants in the APOE gene are associated with improved outcome after anti-VEGF treatment for neovascular AMD. Invest Ophthalmol Vis Sci 2011;52:4072–4079
23. M.K.Adams, J.A.Simpson, A.J.Richardson, D.R.English, K.Z.Aung, G.A.Makeyeva,. Apolipoprotein E gene associations in age-related macular degeneration: the Melbourne Collaborative Cohort Study. Am J Epidemiol 2012;175:511–518
24. S.A.Hagstrom, G.S.Ying, G.J.Pauer, G.M.Sturgill-Short, J.Huang, D.G.Callanan,. Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology 2013;120:593–599
25. A.J.Lotery, J.Gibson, A.J.Cree, S.M.Downes, S.P.Harding, C.A.Rogers,. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age-related macular degeneration in the IVAN study. Ophthalmology 2013;120:2637–2643
26. J.Bergeron-Sawitzke, B.Gold, A.Olsh, S.Schlotterbeck, K.Lemon, K.Visvanathan,. Multilocus analysis of age-related macular degeneration. Eur J Hum Genet 2009;17:1190–1199
27. D.H.Anderson, S.Ozaki, M.Nealon, J.Neitz, R.F.Mullins, G.S.Hageman,. Local cellular sources of apolipoprotein E in the human retina and retinal pigmented epithelium: implications for the process of drusen formation. Am J Ophthalmol 2001;131:767–781
28. F.Simonelli, M.Margaglione, F.Testa, G.Cappucci, M.P.Manitto, R.Brancato,. Apolipoprotein E polymorphisms in age-related macular degeneration in an Italian population. Ophthalmic Res 2001;33:325–328
29. C.M.Bojanowski, D.Shen, E.Y.Chew, B.Ning, K.G.Csaky, W.R.Green,. An apolipoprotein E variant may protect against age-related macular degeneration through cytokine regulation. Environ Mol Mutagen 2006;47:594–602
30. C.P.Pang, L.Baum, W.M.Chan, T.C.Lau, P.M.Poon, D.S.Lam. The apolipoprotein E epsilon4 allele is unlikely to be a major risk factor of age-related macular degeneration in Chinese. Ophthalmologica 2000;214:289–291